Ki67 - An unsuitable marker of gastric cancer prognosis unmasks intratumoral heterogeneity

Journal of Surgical Oncology

Volumn 113, Issue 1, 2016, Pages 46-54

  Böger, Christine ^a   Behrens, Hans Michael ^a   Röcken, Christoph ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Prognostic biomarker; Proliferation; Tumor heterogeneity

Indexed keywords

KI 67 ANTIGEN; TUMOR MARKER;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; EPSTEIN BARR VIRUS INFECTION; FEMALE; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRATUMORAL HETEROGENEITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; TISSUE MICROARRAY; TISSUE SECTION; ADENOCARCINOMA; CANCER GRADING; CHEMISTRY; GENE EXPRESSION REGULATION; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; STOMACH TUMOR; TUMOR INVASION;

ADENOCARCINOMA; AGED; BIOMARKERS, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 84955686399     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.24104     Document Type: Article

References (40)

1. Röcken C, Behrens HM,: Validating the prognostic and discriminating value of the TNM-classification for gastric cancer-A critical appraisal. Eur J Cancer 2015; 51: 577-586.
2. Patel MI, Rhoads KF, Ma Y, et al.,: Seventh edition (2010) of the AJCC/UICC staging system for gastric adenocarcinoma: is there room for improvement ? Ann Surg Oncol 2013; 20: 1631-1638.
3. Yoon HM, Ryu KW, Nam BH, et al.,: Is the new seventh AJCC/UICC staging system appropriate for patients with gastric cancer ? J Am Coll Surg 2012; 214: 88-96.
4. Warneke VS, Behrens HM, Haag J, et al.,: Prognostic and putative predictive biomarkers of gastric cancer for personalized medicine. Diagn Mol Pathol 2013; 22: 127-137.
5. Muller W, Schneiders A, Meier S, et al.,: Immunohistochemical study on the prognostic value of MIB-1 in gastric carcinoma. Br J Cancer 1996; 74: 759-765.
6. Porschen R, Loh B, Hengels KJ, et al.,: Assessment of cell proliferation in colorectal carcinomas using the monoclonal antibody Ki-67. Correlation with pathohistologic criteria and influence of irradiation. Cancer 1989; 64: 2501-2505.
7. Yonemura Y, Ooyama S, Sugiyama K, et al.,: Growth fractions in gastric carcinomas determined with monoclonal antibody Ki-67. Cancer 1990; 65: 1130-1134.
8. Scholzen T, Gerdes J,: The Ki-67 protein: From the known and the unknown. J Cell Physiol 2000; 182: 311-322.
9. Stuart-Harris R, Caldas C, Pinder SE, et al.,: Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 2008; 17: 323-334.
10. He X, Chen Z, Fu T, et al.,: Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: Evidence from a systematic meta-analysis. BMC Cancer 2014; 14: 153.
11. van Velthuysen ML, Groen EJ, van der Noort V, et al.,: Grading of neuroendocrine neoplasms: Mitoses and Ki-67 are both essential. Neuroendocrinology 2014; 100: 221-227.
12. Lauren P,: The two histological main types of gastric carcinoma-Diffuse and so-called intestinal-type carcinoma-An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49.
13. Wittekind C, Oberschmid B,: TNM classification of malignant tumors 2010. Pathologe 2010; 31: 333-338.
14. Packeisen J, Korsching E, Herbst H, et al.,: Demystified... Tissue microarray technology. Mol Pathol 2003; 56: 198-204.
15. Warneke VS, Behrens HM, Boger C, et al.,: Her2/neu testing in gastric cancer: Evaluating the risk of sampling errors. Ann Oncol 2013; 24: 725-733.
16. Benjamini Y,: Discovering the false discovery rate. J R Stat Soc Series B Stat Methodol 2010; 72: 405-416.
17. Guggenheim DE, Shah MA,: Gastric cancer epidemiology and risk factors. J Surg Oncol 2013; 107: 230-236.
18. The Cancer Genome Atlas Research Network: Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-209.
19. Wang K, Yuen ST, Xu J, et al.,: Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 2014; 46: 573-582.
20. Lordick F, Schulze T,: Molecular prognostic factors and new systemic therapies in gastric cancer. Onkologe 2008; 14: 389-395.
21. Gerdes J, Schwab U, Lemke H,: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13-20.
22. Lee HE, Kim MA, Lee BL,: Low Ki-67 proliferation index is an indicator of poor prognosis in gastric cancer. J Surg Oncol 2010; 102: 201-206.
23. Ramires M, David L, Leitao D, et al.,: Ki67 labelling index in gastric carcinomas. An immunohistochemical study using double staining for the evaluation of the proliferative activity of diffuse-type carcinomas. J Pathol 1997; 182: 62-67.
24. de Manzoni G, Verlato G, Tomezzoli A, et al.,: Study on Ki-67 immunoreactivity as a prognostic indicator in patients with advanced gastric cancer. Jpn J Clin Oncol 1998; 28: 534-537.
25. Oshima CT, Iriya K, Forones NM,: Ki-67 as a prognostic marker in colorectal cancer but not in gastric cancer. Neoplasma 2005; 52: 420-424.
26. Czyzewska J, Guzinska-Ustymowicz K, Pryczynicz A, et al.,: Immunohistochemical evaluation of Ki-67, PCNA, and MCM2 proteins proliferation index (PI) in advanced gastric cancer. Folia Histochem Cytobiol 2009; 47: 289-296.
27. Tsamandas AC, Kardamakis D, Tsiamalos P, et al.,: The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome. Anticancer Res 2009; 29: 703-709.
28. Lazar D, Taban S, Sporea I, et al.,: Ki-67 expression in gastric cancer. Results from a prospective study with long-term follow-up. Rom J Morphol Embryol 2010; 51: 655-661.
29. He WL, Li YH, Yang DJ, et al.,: Combined evaluation of centromere protein H and Ki-67 as prognostic biomarker for patients with gastric carcinoma. Eur J Surg Oncol 2013; 39: 141-149.
30. Kroepil F, Dulian A, Vallbohmer D, et al.,: High EpCAM expression is linked to proliferation and lauren classification in gastric cancer. BMC Res Notes 2013; 6: 253.
31. Xiao LJ, Zhao S, Zhao EH, et al.,: Clinicopathological and prognostic significance of Ki-67, caspase-3, and p53 expression in gastric carcinomas. Oncol Lett 2013; 6: 1277-1284.
32. Wu HW, Qin CY, Huang JL, et al.,: Correlations of beta-catenin, Ki67, and Her-2/neu with gastric cancer. Asian Pac J Trop Med 2014; 7: 257-261.
33. Saricanbaz I, Karahacioglu E, Ekinci O, et al.,: Prognostic significance of expression of CD133 and Ki-67 in gastric cancer. Asian Pac J Cancer Prev 2014; 15: 8215-8219.
34. Polley MY, Leung SC, McShane LM, et al.,: An international Ki67 reproducibility study. J Natl Cancer Inst 2013; 105: 1897-1906.
35. Polle MY, Leung SC, Gao D, et al.,: An international study to increase concordance in Ki67 scoring. Mod Pathol 2015; 28: 778-786.
36. Coates AS, Winer EP, Goldhirsch A, et al.,: Tailoring therapies-improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol 2015; 26: 1533-1546.
37. Stahl P, Seeschaaf C, Lebok P, et al.,: Heterogeneity of amplification of HER2, EGFR, CCND1, and MYC in gastric cancer. BMC Gastroenterol 2015; 15: 7.
38. Metzger ML, Behrens HM, Boger C, et al.,: MET in gastric cancer-Discarding a 10% cutoff rule. Histopathol 2015. DOI: 10.1111/his.12745
39. Engel KB, Moore HM,: Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med 2011; 135: 537-543.
40. Arciero AC,: Ki-67 proliferation index and gastric cancer: Answers or more questions. J Surg Oncol 2010; 102: 199-200.